Discontinuation of medication due to adverse events · patients with Shigella dysentery
It is very uncertain whether fluoroquinolones changes adverse events leading to discontinuation of treatment compared with beta‐lactams (very low certainty).
1 finding from 1 review
Intervention not reported
Toxicity (Number of Patients Reporting Adverse Events) · patients with treating osteoarthritis
The intervention showed no clear difference in toxicity (Number of Patients Reporting Adverse Events) (high certainty).
1 finding from 1 review
Intervention not reported
Toxicity (Number of Withdrawals due to Adverse Events) · patients with treating osteoarthritis
The intervention showed no clear difference in toxicity (Number of Withdrawals due to Adverse Events) (moderate certainty).
1 finding from 1 review
Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma
1 finding from 1 review
Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events not measured · atopic eczema
The review found no eligible studies for this question.
1 finding from 1 review
All‐cause serious adverse events 60 weeks (end of study) · patients with chronic obstructive pulmonary disease
It is very uncertain whether macrolide+tetracycline changes all‐cause serious adverse events 60 weeks (end of study) compared with macrolide (very low certainty).
1 finding from 1 review
Grade 3 and 4 hematological adverse events (AE) ‐ anemia · non‐small cell lung cancer in the elderly population
It is very uncertain whether non‐platinum single‐agent changes grade 3 and 4 hematological adverse events (AE) ‐ anemia compared with non‐platinum combination treatment (very low certainty).
1 finding from 1 review
Non‐serious adverse events: serum transaminases elevation · primary hepatocellular carcinoma
It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: serum transaminases elevation compared with TACE (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events: a. mild hypoglycaemia (% of participants)
1 finding from 1 review
Intervention not reported
Adverse events requiring discontinuation [range of median · patients with APL in first complete remission
The intervention probably leads to lower adverse events requiring discontinuation [range of median (moderate certainty).
1 finding from 1 review
no estimate extracted
906 participants
Moderate
Adverse events: number of treatment related adverse events · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: colistimethate dry powder for inhalation… may leads to higher adverse events: number of treatment related adverse events compared with tobramycin (low certainty).
1 finding from 1 review
Adverse events: number of treatment‐related adverse events · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: aztreonam lysine for inhalation probably leads to higher adverse events: number of treatment‐related adverse events compared with tobramycin (moderate certainty).
1 finding from 1 review
Adverse events: number of treatment‐related adverse events · adults and children aged over 12 with CF and P aeruginosa
1 finding from 1 review
Adverse events: any adverse event in the comparative phase · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: continuous cycles alternating aztreonam lysine… showed no clear difference in adverse events: any adverse event in the comparative phase compared with continuous cycles alternating placebo with tobramycin (low certainty).
1 finding from 1 review
Dropouts due to adverse events · adults with trichotillomania
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events including extrapyramidal effects · terminally ill adults with delirium
It is very uncertain whether summary of findings: lorazepam changes number of adverse events including extrapyramidal effectsc compared with chlorpromazine (very low certainty).
1 finding from 1 review
Adverse reaction: apnoea and hypoglycaemia Number of events · neonates receiving EBT
1 finding from 1 review
Number experiencing adverse effects · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: amikacin liposome inhalation suspension (ALIS) showed no clear difference in adverse events: number of participants experiencing any TEAE compared with tobramycin (moderate certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · schizophrenia
1 finding from 1 review